FIELD: medicine.
SUBSTANCE: invention refers to medicine and chemical-pharmaceutical industry and concerns a new immunomodulatory and antiviral agent based on a hybrid molecule of triterpenoid-coumarin derivatives, namely (2-((coumarin-7-yl)oxy)ethyl) 3-hydroxy 20(29)-lupen-28-oate.
EFFECT: declared compound has immunomodulatory properties, having an effect on activation of the humoral response, and expressed antiviral activity against influenza virus A/California/07/09 (H1N1)pdm09 in Balb/c mice in therapeutic and prophylactic mode of application in doses of 10 mg/kg, can be used in medical practice in treating and preventing viral infections.
1 cl, 6 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICOAGULANT AGENT OF INDIRECT ACTION ON BASIS OF DIUMANCAL | 2018 |
|
RU2671983C9 |
| HYBRID COUMARINS WITH INDIRECT ANTICOAGULANT ACTION | 2018 |
|
RU2672062C1 |
| ANTICOAGULANT AGENT OF INDIRECTLY ACTION BASED ON NEW HYBRID MOLECULE OF WARFARIN WITH ESSENTIAL ACID | 2018 |
|
RU2677647C1 |
| ANTIARRHYTHMIC DRUG BASED ON HYBRID MOLECULES OF AMLODIPINE WITH (7-METHOXICUMARIN-4-YL)ACETIC ACID | 2018 |
|
RU2678969C1 |
| 3-O-PROPIONATE ALLOBETULENOLE (19BETA,28-EPOXY-18ALPHA-OLEANANE-3BETA-YL AND PROPIONATE) IMMUNOMODULATORY AGENT | 2013 |
|
RU2554475C2 |
| DERIVATIVES OF 2-H-1-BENZOPYRANE-2-ONE ELICITING ANTI-CALCIUM ACTIVITY | 2003 |
|
RU2242471C1 |
| MEDICAMENT WITH PROLONGED ANTI-CALCIUM ACTIVITY IN THE FORM OF 1/10% INTRAVENOUS SOLUTION | 2004 |
|
RU2255728C1 |
| METHOD FOR BODY PROTECTION AGAINST INFECTION CAUSED BY INFLUENZA A VIRUS SUBTYPE H1N1 STRAINS WITH PREPARATION OF HUMAN ALPHA-2 INTERFERON | 2013 |
|
RU2523554C1 |
| (1S,3aR,4R,7aS)-N-(2,2,4,7a-TETRAMETHYLOCTAHYDRO-1,4-ETHANOINDENE-3a-YL)-ACETAMIDE APPLICATION AS A INFLUENZA VIRUS REPRODUCTION INHIBITOR | 2016 |
|
RU2616255C1 |
| PEPTIDE-BASED COMPOSITION SUPPRESSING REPLICATION OF INFLUENZA A VIRUS | 2018 |
|
RU2695336C1 |
